CMS is delaying the effective date of a rule to let drug manufacturers report multiple best prices on their products if states opt to participate in value-based purchasing models.

CMS Delays Implementing Rule Allowing Multiple Best Prices for Drugs Until Next July

In Federal, RegulatoryNovember 18, 202178 Views

Tom Mirga

The Biden administration said yesterday it is delaying by six months the effective date of a Trump administration final rule to let drug manufacturers report multiple best prices on their products if states opt to participate in value-based purchasing (VBP) models.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Exact matches only

Search in title

Search in content

Search in excerpt

Hidden